IP Library Granted Patent US 7,449,565
Granted Patent B2
US 7,449,565 · App. 11/040,219 · Granted Nov 11, 2008

Chimeric tumor suppressor gene and protein

Assignee: The Trustees of Columbia University in the City of New York
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,449,565
App. No.
11/040,219
Granted
Nov 11, 2008
Kind
B2
Abstract

The present invention relates to chimeric molecules comprising portions of rat PEG-3 (“rPEG-3”) and human GADD34 (“hGADD34”) having apoptotic activity. It is based, at least in part, on the discovery that a chimeric protein comprising amino acids 1-347 of rat PEG-3 fused with residues 418-674 of human GADD34 exhibited anti-proliferative activity when expressed in transformed cells. The present invention provides for this and other rPEG3/hGADD34 chimeras, and the use of such proteins in inhibiting cell proliferation, angiogenesis, and tumor growth.

Claims (7)

1. A nucleic acid molecule encoding a chimeric protein which inhibits cell prolifertion having an N-terminal portion and a C-terminal portion, wherein the N-terminal portion comprises at least amino acid residues 1-270 of rPEG-3 (SEQ ID NO:1) and the C-terminal portion comprises at least amino acid residues 510-674 of hGADD34 (SEQ ID NO:2).

2. The nucleic acid molecule of claim 1 , wherein the N-terminal and C-terminal portions of the encoded chimeric protein are linked via a peptide linker molecule.

3. A nucleic acid molecule encoding a chimeric protein which inhibits cell proliferation having an N-terminal portion and a C-terminal portion, wherein the N-terminal portion comprises a rPEG-3 amino acid sequence beginning at a residue between residue 1 and residue 10 and ending at a residue between residue 300 and residue 375 of rPEG-3 amino acid sequence (SEQ ID NO:1) and the C-terminal portion comprises a hGADD34 amino acid sequence beginning between residue 410 and residue 480 and ending at a residue between 664 and 674 of hGADD34 amino acid sequence (SEQ ID NO:2).

4. The nucleic acid molecule of claim 3 wherein the N-terminal and C-terminal portions of the encoded chimeric protein are linked via a peptide linker molecule.

5. The nucleic acid molecule of claim 3 wherein the N-terminal portion of the encoded chimeric protein comprises amino acid residues 1-347 of rPEG-3 (SEQ ID NO:1 ) and the C-terminal portion comprises amino acid residues 418-674 of hGADD34 (SEQ ID NO:2) wherein at least a leucine residue is located between said amino acid 347 of rPEG-3 (SEQ ID NO:1 ) and said residue 418 of hGADD34 (SEQ ID NO:2).

6. The nucleic acid molecule of claim 5 , wherein the amino acid sequence of the encoded protein is (SEQ ID NO:5).

7. The nucleic acid molecule of claim 5 wherein the N-terminal and C-terminal portions of the encoded chimeric protein are linked via a peptide linker molecule.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2020
From: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
To: FISHER, PAUL B.
Reel/Frame 051974/0507 →
CONFIRMATORY LICENSE Recorded Sep 21, 2010
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025019/0033 →
CONFIRMATORY LICENSE Recorded Feb 11, 2009
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 022244/0415 →
Continuity (1)
Related Publication 20060166220A1 · Jul 27, 2006